Todos Medical Now Accepting Cryptocurrency for the Buy of Tollovid® and Tollovid Day by day™ by Coinbase Commerce Cryptocurrency accepted embrace Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Bitcoin Money (BCH) and Litecoin (LTC)



New York, NY & Tel Aviv, Israel, Sept. 19, 2021 (GLOBE NEWSWIRE) — (by way of Blockchain Wire) Todos Medical, Ltd. (OTCQB: TOMDF), a medical diagnostics and options firm with complete product choices, introduced that it’s now accepting Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Bitcoin Money (BCH) and Litecoin (LTC) as fee for the Firm’s proprietary 3CL protease inhibitor wellness merchandise Tollovid® and Tollovid Day by day™. The Firm is ready to settle for these types of funds by its web site when purchasers choose Coinbase Commerce because the type of fee at checkout.

“We imagine strongly that everybody ought to take Tollovid to help their immune operate throughout instances of great immune problem and needs to be taking Tollovid Day by day every day with a view to preserve constant, wholesome immune operate,” stated Gerald E. Commissiong, President & CEO of Todos Medical. “The power to just accept broadly utilized cryptocurrency is a crucial step as we broaden our advertising efforts round our novel 3CL protease inhibitor wellness merchandise.”

Tollovid and Tollovid Day by day are dietary complement merchandise which have each acquired Certificates of Free Sale from the U.S. Meals & Drug Administration (FDA), authorizing the advertising and sale of those merchandise in the USA. The FDA has allowed the Firm to make two particular claims with reference to every product:

  1. Tollovid and Tollovid Day by day assist to help and preserve wholesome immune operate; and
  2. Tollovid and Tollovid Day by day are 3CL protease inhibitors.

Tollovid is focused to prospects that want most immune help, whereas Tollovid Day by day addresses prospects that require or may gain advantage from every day immune help. Each Tollovid and Tollovid Day by day will be bought by way of subscription and now, using cryptocurrency

For extra data, please go to For extra data on the Firm’s CLIA/CAP licensed lab Provista Diagnostics, Inc. please go to

About Todos Medical Ltd.

Based in Rehovot, Israel with places of work in New York Metropolis, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic options for the early detection of quite a lot of cancers. In 20201, Todos accomplished the acquisition of U.S.-based medical diagnostics firm Provista Diagnostics, Inc. to realize rights to its Alpharetta, Georgia-based CLIA/CAP licensed lab at the moment performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast most cancers blood check. The Firm’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening know-how utilizing peripheral blood evaluation that deploys deep examination into most cancers’s affect on the immune system, in search of biochemical modifications in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening checks, TMB-1 and TMB-2, have acquired a CE mark in Europe. Todos is concentrated on the commercialization of Videssa and can convey the TBIA checks to market thereafter.

Todos has entered right into a three way partnership with NLC Pharma focusing on diagnostic and testing options to handle the COVID-19 pandemic. The Joint-Enterprise is pursuing the event of diagnostic checks focusing on the 3CL protease, in addition to 3CL protease inhibitors that focus on a basic reproductive mechanism of coronaviruses. The Firm’s proprietary therapeutic candidate Tollovir™ is at the moment in a Part 2 medical trial to deal with hospitalized COVID-19 sufferers in Israel, and is making ready to provoke Part 2/3 medical trials for each hospitalized and non-hospitalized sufferers in Israel.

Todos can also be creating blood checks for the early detection of neurodegenerative issues, resembling Alzheimer’s illness. The Lymphocyte Proliferation Check (LymPro Check™) is a diagnostic blood check that determines the flexibility of peripheral blood lymphocytes (PBLs) and monocytes to resist an exogenous mitogenic stimulation that induces them to enter the cell cycle. It’s believed that sure ailments, most notably Alzheimer’s illness, are the results of compromised mobile equipment that results in aberrant cell cycle re-entry by neurons, which then results in apoptosis. LymPro is exclusive in using peripheral blood lymphocytes as a surrogate for neuronal cell operate, suggesting a typical relationship between PBLs and neurons within the mind. 

Todos can also be distributing sure (COVID-19) testing supplies and provides to CLIA-certified labs in the USA. The merchandise cowl a number of suppliers of PCR testing kits, extraction kits, automation supplies and provides, in addition to COVID-19 antibody and antigen testing kits. 

For extra data, please go to

Ahead-looking Statements

Sure statements contained on this press launch might represent forward-looking statements. For instance, forward-looking statements are used when discussing our anticipated medical improvement applications and medical trials. These forward-looking statements are based mostly solely on present expectations of administration, and are topic to important dangers and uncertainties that would trigger precise outcomes to vary materially from these described within the forward-looking statements, together with the dangers and uncertainties associated to the progress, timing, value, and outcomes of medical trials and product improvement applications; difficulties or delays in acquiring regulatory approval or patent safety for product candidates; competitors from different biotechnology corporations; and our skill to acquire further funding required to conduct our analysis, improvement and commercialization actions. As well as, the next components, amongst others, might trigger precise outcomes to vary materially from these described within the forward-looking statements: modifications in know-how and market necessities; delays or obstacles in launching our medical trials; modifications in laws; incapacity to well timed develop and introduce new applied sciences, merchandise and functions; lack of validation of our know-how as we progress additional and lack of acceptance of our strategies by the scientific neighborhood; incapacity to retain or appeal to key workers whose information is crucial to the event of our merchandise; unexpected scientific difficulties that will develop with our course of; higher value of ultimate product than anticipated; lack of market share and stress on pricing ensuing from competitors; and laboratory outcomes that don’t translate to equally good ends in actual settings, all of which might trigger the precise outcomes or efficiency to vary materially from these contemplated in such forward-looking statements. Besides as in any other case required by legislation, Todos Medical doesn’t undertake any obligation to publicly launch any revisions to those forward-looking statements to mirror occasions or circumstances after the date hereof or to mirror the incidence of unanticipated occasions. For a extra detailed description of the dangers and uncertainties affecting Todos Medical, please check with its stories filed infrequently with the U.S. Securities and Trade Fee.

Richard Galterio Todos Medical, Ltd 732-642-7770  Daniel Hirsch Todos Medical, Ltd 347-699-0029

Primary Logo




Please enter your comment!
Please enter your name here